Invention Grant
- Patent Title: Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
-
Application No.: US17140357Application Date: 2021-01-04
-
Publication No.: US11571471B2Publication Date: 2023-02-07
- Inventor: Robin Steigerwald , Markus Kalla
- Applicant: Bavarian Nordic A/S
- Applicant Address: DK Hellerup
- Assignee: Bavarian Nordic A/S
- Current Assignee: Bavarian Nordic A/S
- Current Assignee Address: DK Hellerup
- Priority: EP16153394 20160129,EP16157055 20160224,EP16185012 20160819
- Main IPC: C12N15/863
- IPC: C12N15/863 ; A61K39/15 ; A61K39/12 ; C12N15/86 ; C07K14/005 ; A61P31/14 ; C12N7/00 ; A61K39/00

Abstract:
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
Public/Granted literature
- US20210205439A1 Recombinant Modified Vaccinia Virus Ankara (MVA) Equine Encephalitis Virus Vaccine Public/Granted day:2021-07-08
Information query
IPC分类: